Evidence map›Paper›PMID 41547704›Full record

ArticleScientific reports2026

Combined effects of physical activity and diabetes medications on glycemic control: a real-world data study.

Kenta Yamamoto, Riko Kai, Atsuya Inano, Masaki Mizuno

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kenta YamamotoFaculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo, 164-8530, Japan. kenta.yamamoto@thu.ac.jp.
Riko KaiFaculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo, 164-8530, Japan.
Atsuya InanoFaculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo, 164-8530, Japan.
Masaki MizunoDepartment of Applied Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Funding

Japan Society for the Promotion of Science JP20K11422
6 · The paper itself

Abstract

Monitoring and modeling population health is essential for understanding the impact of lifestyle behaviors and pharmacologic therapies on chronic disease management. In this study, we used a nationwide Japanese health insurance claims and health checkup database to investigate the associations between physical activity and glycemic control among 24,830 treatment-naïve adults with type 2 diabetes receiving DPP-4 inhibitors, SGLT2 inhibitors, or metformin. The odds of achieving hemoglobin A1c (HbA1c) < 6.5% at follow-up were assessed according to physical activity status, determined using standardized questionnaires. In this real-world population, physically active individuals had higher odds of achieving glycemic control than sedentary individuals among those treated with DPP-4 inhibitors or SGLT2 inhibitors, whereas no statistically significant association was observed among those treated with metformin. These findings support the potential value of integrating physical activity with pharmacologic therapy in type 2 diabetes management in real-world clinical settings.

Indexed as

Diabetes Mellitus, Type 2ExerciseGlycemic ControlHypoglycemic AgentsAdultAgedBlood GlucoseDipeptidyl-Peptidase IV InhibitorsFemaleGlycated HemoglobinHumansMaleMetforminMiddle AgedSodium-Glucose Transporter 2 InhibitorsBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsCombination therapyDPP-4 inhibitorMetforminPhysical activitySGLT2 inhibitor

Identifiers

PMID41547704
PMCPMC12891579

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.